NeoGenomics, Inc. NEO 深 沪
已收盘 05-22 16:00:00 美东时间
9.23
+0.120
+1.32%
华盛通- 最 高9.36
- 今 开9.11
- 成交量 77.88万股
- 最 低 9.07
- 昨 收 9.11
- 总市值 120.19万
- 52周最高 13.74
- 市盈率 静 --
- 换手率 0.60%
- 52周最低 4.72
- 委 比 -75.17%
- 总股本 0.00亿
- 历史最高 61.57
- 量 比 0.61
- 振 幅 3.18%
- 历史最低 0.96
- 每 手 1
- 风险率 2.06%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For May 12, 2026
Companies Reporting Before The Bell • Sionna Therapeutics (NASDAQ:SION) is proj...
05-12 19:11
美股大行评级 | 瑞银：维持Visa"买入"评级！目标价从390美元升至410美元
今日重点评级关注：HC Wainwright & Co.：维持Protara Therapeutics"买入"评级，目标价从23美元升至27美元；BTIG：维持Black Diamond Therapeutic"买入"评级，目标价从10美元升至11美元
04-30 19:24
Leerink Partners Upgrades NeoGenomics to Outperform, Raises Price Target to $25
Leerink Partners analyst Puneet Souda upgrades NeoGenomics (NASDAQ:NEO) from Market Perform to Outperform and raises the price target from $12 to $25.
04-29 21:10
财报速睇 | NeoGenomics, Inc. 2026财年Q1营收1.87亿美元，同比增长11.1%；归母净利润亏损0.17亿美元，同比亏损缩窄34.0%
华盛资讯4月29日讯，NeoGenomics, Inc.公布2026财年Q1业绩，公司Q1营收1.87亿美元，同比增长11.1%，归母净利润亏损0.17亿美元，同比亏损缩窄34.0%。
04-29 07:22
财报速睇 | NeoGenomics, Inc. 2026财年Q1营收1.87亿美元，同比增长11.1%；归母净利润亏损0.17亿美元，同比亏损缩窄34.0%
华盛资讯4月29日讯，NeoGenomics, Inc.公布2026财年Q1业绩，公司Q1营收1.87亿美元，同比增长11.1%，归母净利润亏损0.17亿美元，同比亏损缩窄34.0%。
04-29 07:02
NeoGenomics Raises FY2026 Sales Guidance from $793.000M-$801.000M to $797.000M-$803.000M vs $796.641M Est
NeoGenomics (NASDAQ:NEO) raises FY2026 sales outlook from $793.000 million-$801.000 million to $797.000 million-$803.000 million vs $796.641 million estimate.
04-29 04:11
NeoGenomics Q1 Adj. EPS $0.01, Inline, Sales $186.672M Beat $184.509M Estimate
NeoGenomics (NASDAQ:NEO) reported quarterly earnings of $0.01 per share which met the analyst consensus estimate. The company reported quarterly sales of $186.672 million which beat the analyst consensus estimate of
04-29 04:09
Earnings Scheduled For April 28, 2026
Companies Reporting Before The Bell • LGI Homes (NASDAQ:LGIH) is likely to repo...
04-28 19:11
NeoGenomics Announces Availability Of Its Oncology Testing Portfolio Through Epic Aura, Enabling Access To Oncologists And Health Systems Across The U.S.
Through this integration, physicians can order NeoGenomics' comprehensive suite of tests, spanning solid tumors and hematologic malignancies, and view results in the same system they use to manage patient care. This
04-23 19:17
NeoGenomics To Showcase AI-Driven Cancer Research And Data Insights At Major Conference
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced it will present eight scientific posters and one oral presentation at the AACR Annual
04-13 19:16
